Author

C. A. Natale

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Pathology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 4 Organism:mouse· 4 Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 3 Research Focus:drug response / drug discovery· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:differential expression· 2

Frequent Co-Authors

T. W. Ridky· 4 shared J. Li· 2 shared J. T. Seykora· 2 shared A. B. McNally· 1 shared A. Dahal· 1 shared A. Horton· 1 shared A. Imulinde Sugi· 1 shared A. Trautz· 1 shared

Activity by Year

2017-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

T. W. Ridky

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Ovariectomy-Induced Arterial Stiffening Differs from Vascular Aging and is Reversed by GPER Activation

I. Kilanowski-Doroh, A. B. McNally, T. J. Wong, B. Visniauskas, S. A. Blessinger, A. Imulinde Sugi, C. Richard, Z. Diaz, A. Horton, C. A. Natale, B. O. Ogola, S. H. Lindsey

This study shows that ovariectomy-induced arterial stiffening differs from vascular aging and can be reversed by GPER activation in mice.

bioRxiv · Aug 10, 2023 · PreprintPharmacology & Toxicology

Analysis of human GPER expression in normal tissues and select cancers using immunohistochemistry

C. A. Natale, J. T. Seykora, T. W. Ridky

This study uses immunohistochemistry with a new antibody to show GPER expression varies across normal and cancer tissues.

bioRxiv · Mar 9, 2023 · PreprintPathology

CHRM1 is a Druggable Melanoma Target Whose Endogenous Activity is Determined by Inherited Genetic Variation in DOPA Production

M. Doepner, C. A. Natale, I. Y. Lee, S. Venkat, S. H. Kim, J. A. Katzenellenbogen, B. S. Katzenellenbogen, M. Feigin, T. W. Ridky

This study identifies CHRM1 as a druggable melanoma target influenced by genetic variation in DOPA production, showing DOPA inhibits CHRM1 to suppress melanoma proliferation.

bioRxiv · Mar 3, 2021 · PreprintCancer Biology

ZIP9 is a Druggable Determinant of Sex Differences in Melanoma

C. Aguirre-Portoles, R. Payne, A. Trautz, J. K. Foskett, C. A. Natale, J. T. Seykora, T. W. Ridky

The paper identifies ZIP9 as a target of testosterone in melanoma and shows that androgen receptor inhibitors can block ZIP9 to suppress melanoma growth in males.

bioRxiv · Mar 12, 2020Cancer Biology

Pharmacologic activation of G protein-coupled estrogen receptor inhibits pancreatic ductal adenocarcinoma

C. A. Natale, J. Li, T. Dentchev, B. Capell, J. Seykora, B. Stanger, T. Ridky

This study shows that activating the GPER receptor with G-1 inhibits PDAC growth, reduces c-Myc and PD-L1, and enhances immunotherapy response in mouse models and human tumors.

bioRxiv · Apr 13, 2019Cancer Biology

Non-classical estrogen signaling inhibits melanoma and improves response to PD-1 blockade

C. A. Natale, J. Li, J. Zhang, A. Dahal, B. Z. Stanger, T. W. Ridky

This study shows that GPER activation inhibits melanoma growth and enhances response to PD-1 blockade by promoting differentiation and reducing immune suppressive proteins.

bioRxiv · Jun 6, 2017Cancer Biology